NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Durvalumab with gemcitabine and cisplatin for untreated unresectable or advanced biliary tract cancer ID4031

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
Company • AstraZeneca (durvalumab) Patient/carer groups • Addenbrookes Liver Transplant Association • AMMF – The Cholangiocarcinoma Charity • Black Health Agency for Equality • Bladder and Bowel Community • British Liver Trust • Cancer 52 • Cancer Black Care • Cancer Equality • GUTS UK • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Liver4Life • Macmillan Cancer Support • Maggie's Centres • Marie Curie • PBC Foundation • Pelican Cancer Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care Healthcare professional groups • Association of Anaesthetists • Association of Cancer Physicians • Association of Coloproctology of Great Britain and Ireland • Association of Surgeons of Great Britain and Ireland • Association of Upper Gastrointestinal	General • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • Scottish Medicines Consortium • Scottish Society of Gastroenterology • Welsh Health Specialised Services Committee • Welsh Government Possible comparator companies • Accord Healthcare (capecitabine, cisplatin, fluorouracil, gemcitabine, oxaliplatin) • Dr. Reddy's Laboratories (capecitabine) • Glenmark Pharmaceuticals (capecitabine) • Medac Pharma (fluorouracil, oxaliplatin) • Morningside Healthcare (capecitabine) • Pfizer (cisplatin, fluorouracil, gemcitabine, oxaliplatin) • Sandoz (cisplatin) • Seacross Pharmaceuticals (oxaliplatin)

Consultees	**Commentators (no right to submit or appeal)**
Surgeons of Great Britain and Ireland • British Association for the Study of the Liver • British Association of Surgical Oncology • British Geriatrics Society • British Institute of Radiology • British Psychosocial Oncology Society • British Society of Gastroenterology • British Society of Interventional Radiology • Cancer Research UK • Cholangiocarcinoma-UK • Primary Care Society for Gastroenterology • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association • UK Oncology Nursing Society <u>Others</u> • Department of Health and Social Care • NHS England	• Sun Pharma (gemcitabine, oxaliplatin) <u>Relevant research groups</u> • Cochrane Hepato-Biliary Group • Cochrane UK • Foundation for Liver Research • Genomics England • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Institute for Health Research <u>Associated Public Health groups</u> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

<u>Consultees</u>

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient

organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement[1], respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

[1] Non company consultees are invited to submit statements relevant to the group they are representing.

